Cargando…
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
BACKGROUND: We aimed to evaluate relationships between clinical outcomes and explanatory variables by network clustering analysis using data from a post marketing surveillance (PMS) study of castration-resistant prostate cancer (CRPC) patients. METHODS: The PMS was a prospective, multicenter, observ...
Autores principales: | Kazama, Hirotaka, Kawaguchi, Osamu, Seto, Takeshi, Suzuki, Kazuhiro, Matsuyama, Hideyasu, Matsubara, Nobuaki, Tajima, Yuki, Fukao, Taro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052565/ https://www.ncbi.nlm.nih.gov/pubmed/35484517 http://dx.doi.org/10.1186/s12885-022-09509-0 |
Ejemplares similares
-
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study
por: Suzuki, Kazuhiro, et al.
Publicado: (2019) -
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
por: Matsuyama, Hideyasu, et al.
Publicado: (2023) -
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study
por: Matsuyama, Hideyasu, et al.
Publicado: (2020) -
Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020) -
Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)